Contents

Current Pharmaceutical Design, Volume 19 - Number 29

Editorial (Hot Topic: Update on Treatment Strategies in Patients with Non-alcoholic Fatty Liver Disease)

, 19(29): 5167 - 5168

Salvatore Petta


DOI: 10.2174/1381612811319290001




Epidemiology and Natural History of Patients with NAFLD

, 19(29): 5169 - 5176

Neeraj Bhala, Ramy Ibrahim Kamal Jouness and Elisabetta Bugianesi


DOI: 10.2174/13816128113199990336




Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD

, 19(29): 5177 - 5192

Amedeo Lonardo, Silvia Sookoian, Michel Chonchol, Paola Loria and Giovanni Targher


DOI: 10.2174/1381612811319290003




Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease

, 19(29): 5193 - 5218

Salvatore Petta, Aase Handberg and Antonio Craxi


DOI: 10.2174/1381612811319290004




Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

, 19(29): 5219 - 5238

Paola Dongiovanni, Quentin M. Anstee and Luca Valenti


DOI: 10.2174/13816128113199990381




From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights

, 19(29): 5239 - 5249

Samuele De Minicis, Chris Day and Gianluca Svegliati-Baroni


DOI: 10.2174/1381612811319290006




Pathophysiology of NASH: Perspectives for a Targeted Treatment

, 19(29): 5250 - 5269

Fabio Marra and Sophie Lotersztajn


DOI: 10.2174/13816128113199990344




The Role of Lifestyle Change in the Prevention and Treatment of NAFLD

, 19(29): 5270 - 5279

Elena Centis, Rebecca Marzocchi, Alessandro Suppini, Riccardo Dalle Grave, Nicola Villanova, Ingrid J Hickman and Giulio Marchesini


DOI: 10.2174/1381612811319290008




Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD

, 19(29): 5280 - 5296

Lucia Carulli, Mauro Maurantonio, Lionel Hebbard, Enrica Baldelli, Paola Loria and Jacob George


DOI: 10.2174/1381612811319290009




Antioxidant Therapy and Drugs Interfering with Lipid Metabolism: Could They Be Effective in NAFLD Patients?

, 19(29): 5297 - 5313

Giovanni Musso, Rodolphe Anty and Salvatore Petta


DOI: 10.2174/1381612811319290010




Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target

, 19(29): 5314 - 5324

Luca Miele, Giuseppe Marrone, Cristiano Lauritano, Consuelo Cefalo, Antonio Gasbarrini, Chris Day and Antonio Grieco


DOI: 10.2174/1381612811319290011




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science